Table 2.
Calculated pharmacokinetic parameters following i.v. and s.c. dosing with Albuleukin in BALB/c mice
| Parameter | Albuleukin parameters (mean ± SEM) | rIL-2 parameters (mean ± SEM) | ||
|---|---|---|---|---|
| Route of administration | i.v. | s.c. | i.v. | s.c. |
| Dose (μg/kg) | 500 | 500 | 500 | 500 |
| AUC (h×μg/ml) | 75.2±9.5 | 33.5±2.8 | 1.51±0.05 | 1.59±0.11 |
| CL or CL/F (ml/h/kg) | 6.65±0.84 | 14.9±1.2 | 330±12.0 | 314±21 |
| Vss or Vss/F (ml/kg) | 74.4±12 | 128±6.8 | 86.8±5.5 | 429±48 |
| Vi (ml/kg) | NA | NA | 38.5±0.8 | NA |
| t1/2,term (h) | 7.75±0.49 | 5.96±0.38 | 0.32±0.03 | 0.95±0.06 |
| t1/2,abs (h) | NA | 5.96±0.38 | NA | 0.20±0.04 |
| t1/2,α (h) | NA | NA | 0.047±0.005 | NA |
| % AUCα | NA | NA | 49.9 | NA |
| Cmax (μg/ml) | 6.72±1.1 | 1.43±0.08 | 13.0±0.28 | 0.77±0.06 |
| Tmax (h) | 0 | 8.60±0.54 | 0 | 0.57±0.07 |
| s.c. Bioavailability (%) | 45 | 105 | ||
AUC area under the plasma concentration curve, CL clearance, Vss volume of distribution at steady state, Vi initial volume of distribution, F bioavailable fraction, t1/2,term terminal half-life, t1/2,abs absorption half-life, t1/2,α initial phase half-life, Cmax maximal plasma concentration, Tmax time to maximal plasma concentration, NA not applicable